These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22749643)

  • 61. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
    Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
    Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.
    Olesen PH; Sørensen AR; Ursø B; Kurtzhals P; Bowler AN; Ehrbar U; Hansen BF
    J Med Chem; 2003 Jul; 46(15):3333-41. PubMed ID: 12852764
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
    Dessalew N; Bharatam PV
    Bioorg Med Chem; 2007 Jun; 15(11):3728-36. PubMed ID: 17399989
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
    Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L
    J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
    Kohara T; Nakayama K; Watanabe K; Kusaka SI; Sakai D; Tanaka H; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Mori A; Tanaka S; Bessho T; Takiguchi-Hayashi K; Horikawa T
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3733-3738. PubMed ID: 28712706
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
    Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.
    Redenti S; Marcovich I; De Vita T; Pérez C; De Zorzi R; Demitri N; Perez DI; Bottegoni G; Bisignano P; Bissaro M; Moro S; Martinez A; Storici P; Spalluto G; Cavalli A; Federico S
    ChemMedChem; 2019 Feb; 14(3):310-314. PubMed ID: 30548443
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.
    Pandey MK; DeGrado TR
    Theranostics; 2016; 6(4):571-93. PubMed ID: 26941849
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
    Furlotti G; Alisi MA; Cazzolla N; Dragone P; Durando L; Magarò G; Mancini F; Mangano G; Ombrato R; Vitiello M; Armirotti A; Capurro V; Lanfranco M; Ottonello G; Summa M; Reggiani A
    J Med Chem; 2015 Nov; 58(22):8920-37. PubMed ID: 26486317
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.
    Khanfar MA; Asal BA; Mudit M; Kaddoumi A; El Sayed KA
    Bioorg Med Chem; 2009 Aug; 17(16):6032-9. PubMed ID: 19616957
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism.
    MacAulay K; Doble BW; Patel S; Hansotia T; Sinclair EM; Drucker DJ; Nagy A; Woodgett JR
    Cell Metab; 2007 Oct; 6(4):329-37. PubMed ID: 17908561
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design, Synthesis and Biological Evaluation of 7-Chloro-9
    Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
    Phiel CJ; Wilson CA; Lee VM; Klein PS
    Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
    Hamann M; Alonso D; Martín-Aparicio E; Fuertes A; Pérez-Puerto MJ; Castro A; Morales S; Navarro ML; Del Monte-Millán M; Medina M; Pennaka H; Balaiah A; Peng J; Cook J; Wahyuono S; Martínez A
    J Nat Prod; 2007 Sep; 70(9):1397-405. PubMed ID: 17708655
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa.
    Marchena M; Villarejo-Zori B; Zaldivar-Diez J; Palomo V; Gil C; Hernández-Sánchez C; Martínez A; de la Rosa EJ
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):522-526. PubMed ID: 28114834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.
    Bernard-Gauthier V; Mossine AV; Knight A; Patnaik D; Zhao WN; Cheng C; Krishnan HS; Xuan LL; Chindavong PS; Reis SA; Chen JM; Shao X; Stauff J; Arteaga J; Sherman P; Salem N; Bonsall D; Amaral B; Varlow C; Wells L; Martarello L; Patel S; Liang SH; Kurumbail RG; Haggarty SJ; Scott PJH; Vasdev N
    J Med Chem; 2019 Nov; 62(21):9600-9617. PubMed ID: 31535859
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
    Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.
    Liang SH; Chen JM; Normandin MD; Chang JS; Chang GC; Taylor CK; Trapa P; Plummer MS; Para KS; Conn EL; Lopresti-Morrow L; Lanyon LF; Cook JM; Richter KE; Nolan CE; Schachter JB; Janat F; Che Y; Shanmugasundaram V; Lefker BA; Enerson BE; Livni E; Wang L; Guehl NJ; Patnaik D; Wagner FF; Perlis R; Holson EB; Haggarty SJ; El Fakhri G; Kurumbail RG; Vasdev N
    Angew Chem Int Ed Engl; 2016 Aug; 55(33):9601-5. PubMed ID: 27355874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.